Compounds for the treatment of female sexual dysfunction

• US 20050070499A1
• Filed: 10/15/2003
• Published: 03/31/2005
• Est. Priority Date: 11/08/1999
• Status: Abandoned Application

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Wayman, Christopher Peter, Maw, Graham Nigel
• Application Number:
  US10/686,349
• Publication Number:
  US 20050070499A1
• Time in Patent Office: Days
• US Class Current: 514/47
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/4412 having oxo groups directly attached to the heterocyclic ring
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: C12Q 1/44 involving esterase
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
• CPC Class Codes: G01N 33/689 related to pregnancy or the gonads
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

A method of treating a female suffering from FSD, in particular FSAD, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

Claims

1-29. -29. (cancelled).

30. A method for treating female sexual dysfunction comprising the step of delivering to a female suffering from female sexual dysfunction a therapeutically effective amount of a neuropeptide Y inhibitor, wherein said inhititor is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.

31. The method according to claim 30 wherein said inhibitor has a selective effect on the genitalia of said female.

32. The method according to claim 30 wherein in the absence of sexual stimulation the inhibitor has no or a negligible effect in causing an increase in genital blood flow in said female.

33. The method according to claim 30 wherein said neuropeptide Y is a mediator of genital vasorelaxation.

34. The method according to claim 30 wherein said neuropeptide Y inhibitor is a mediator of vaginal or clitoral vasorelaxation.

35. The method according to claim 30 wherein said neuropeptide Y inhibitor is delivered before or during sexual stimulation.

36. The method according to claim 30 wherein said inhibitor is delivered orally.

37. The method according to claim 30 wherein said amount of neuropeptide Y inhibitor delivered causes potentiation of cAMP.

38. The method according to claim 37 wherein said cAMP is endogenous cAMP.

39. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 100 nM.

40. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 75 nM.

41. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 50 nM.

42. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 25 nM.

43. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 20 nM.

44. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 15 nM.

45. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 10 nM.

46. The method according to claim 30 wherein said inhibitor has a K_i value of less than about 5 nM.

47. The method according to claim 30 wherein said inhibitor is delivered in combination with one or more other pharmaceutically active agents.

48. The method according to claim 30 wherein said NPY is neuropeptide YY1.

49. A method for treating female sexual arousal disorder comprising the step of orally delivering to a female suffering from female sexual arousal disorder a therapeutically effective amount of a neuropeptide Y inhibitor, wherein said inhibitor is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.

50. The method according to claim 49 wherein said inhibitor has a selective effect on the genitalia of said female.

51. The method according to claim 49 wherein in the absence of sexual stimulation said inhibitor has no or a negligible effect in causing an increase in genital blood flow in said female.

52. The method according to claim 49 wherein said neuropeptide Y inhibitor is a mediator of genital vasorelaxation.

53. The method according to claim 49 wherein said neuropeptide Y inhibitor is a mediator of vaginal or clitoral vasorelaxation.

54. The method according to claim 49 wherein said neuropeptide Y inhibitor is administered orally.

55. The method according to claim 49 wherein said neuropeptide Y inhibitor is delivered before or during sexual stimulation.

56. The method according to claim 49 wherein said amount of inhibitor causes potentiation of cAMP in the genitalia of said female.

57. The method according to claim 56 where said cAMP is endogenous cAMP.

58. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 100 nM.

59. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 75 nM.

60. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 50 nM.

61. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 25 nM.

62. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 20 nM.

63. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 15 nM.

64. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 10 nM.

65. The method according to claim 49 wherein said inhibitor has a K_i value of less than about 5 nM.

66. The method according to claim 49 wherein said inhibitor is delivered in combination with one or more other pharmaceutically active agents.

67. The method according to claim 49 wherein said NPY is neuropeptide YY1.